written on 20.11.2019

Thailand Pharma Report November 2019


Thailand is in the midst of an economic transformation with healthcare at its heart. With four years of around three-four percent annual GDP growth behind it, ASEAN’s second-largest economy has implemented an ‘Industry 4.0’ policy through which it is attempting to prioritise R&D and innovation in a number of key industries, including healthcare and the life sciences.


Already a regional frontrunner in terms of the implementation of universal healthcare, Thailand is aiming to scale the value chain and grow its footprint in specific niches where it can excel, including clinical research and infectious disease vaccine production. The country is also aiming to cement its reputation as one of Asia’s leading medical tourism hubs, attracting patients from across the globe with high-quality yet affordable healthcare.

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here